KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Gains from Investment Securities (2016 - 2025)

Vertex Pharmaceuticals has reported Gains from Investment Securities over the past 17 years, most recently at -$1.3 billion for Q4 2025.

  • Quarterly results put Gains from Investment Securities at -$1.3 billion for Q4 2025, down 437.97% from a year ago — trailing twelve months through Dec 2025 was -$113.4 million (down 127.06% YoY), and the annual figure for FY2025 was -$113.4 million, down 128.0%.
  • Gains from Investment Securities for Q4 2025 was -$1.3 billion at Vertex Pharmaceuticals, down from $1.2 billion in the prior quarter.
  • Over the last five years, Gains from Investment Securities for VRTX hit a ceiling of $1.6 billion in Q4 2023 and a floor of -$1.3 billion in Q4 2025.
  • Median Gains from Investment Securities over the past 5 years was $1.4 million (2021), compared with a mean of $71.7 million.
  • Peak annual rise in Gains from Investment Securities hit 391466.67% in 2025, while the deepest fall reached 36460.0% in 2025.
  • Vertex Pharmaceuticals' Gains from Investment Securities stood at $94.8 million in 2021, then tumbled by 935.76% to -$792.3 million in 2022, then skyrocketed by 307.55% to $1.6 billion in 2023, then plummeted by 76.78% to $381.9 million in 2024, then plummeted by 437.97% to -$1.3 billion in 2025.
  • The last three reported values for Gains from Investment Securities were -$1.3 billion (Q4 2025), $1.2 billion (Q3 2025), and -$181.8 million (Q2 2025) per Business Quant data.